Genentech, the maker of Avastin and other expensive cancer drugs, paid physicians and teaching hospitals more than any other drug or device company in 2014, according to a new round of data posted to the CMS' Open Payments website.
The makers of the potent painkiller OxyContin have pulled out of a federal meeting to review the company's harder-to-abuse version of the much-debated drug.
The 21st Century Cures Act, a fast-moving bill aimed at fueling medical innovation, would cost $106 billion to implement and its cost-saving provisions—including limiting Medicaid pay for durable medical equipment—would yield $12 billion over the next decade, according to the CBO.
Federal regulators on Monday approved the blood clot prevention drug Kengreal made by the Medicines Co. for patients undergoing angioplasty procedures. The approval comes after a decade and $200 million were spent developing the drug.
Clinical drug trials of an experimental treatment for Ebola have stopped after it was found unlikely to be effective. Health officials have been looking to abate the effects of the virus strain that has ravaged West Africa for more than a year.
A new tool will allow oncologists to compare various drug treatments for four common cancers based on survival, side effects and costs. The framework is part of a broader effort to help physicians and patients choose appropriate therapies amid the skyrocketing costs of cancer drugs.
The first approved generic of the multiple sclerosis drug Copaxone launched this week after a federal appeals court upheld a ruling Thursday that drugmaker Teva Pharmaceuticals' patent on its best-selling drug was invalid. The generic Glatopa's cost per month is estimated at $5,000, compared with...
Dublin-based Botox maker Allergan has agreed to acquire Kythera Biopharmaceuticals for more than $2 billion. Allergan hopes to bank on the medical cosmetic drug firm's recently approved treatment for double chins.
House Energy and Commerce Committee Chairman Fred Upton (R-Mich.) is aiming to have as many as 350 votes or 80% of the members of the House supporting the 21st Century Cures Act, also known as H.R. 6.
FDA advisory panels this week recommended approval of two drugs that may significantly lower cholesterol. But experts warn the potential high cost for these blockbuster drugs could limit their access and once again raise concerns about skyrocketing prescription costs.
Bayer on Wednesday announced it is selling its diabetes-care business to Panasonic Healthcare Holdings Co., in a deal valued at just over $1.1 billion (1 billion euros). The German drugmaker is focusing on prescription and over-the-counter drugs, as well as its crop science business.
The costs of prescription drugs have grown more quickly than any other part of the healthcare industry, and a new report estimates a small portion of breakthrough specialty drugs will further strain the budgets of federal and state healthcare programs.